Development of predictive markers for drug-susceptibility in blood by genomic analysis using PDX models

2017 Fiscal Year Final Research Report

• Project/Area Number: 15H04973
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Urology
• Research Institution: Kumamoto University (2017); Kyoto University (2015-2016)
• Principal Investigator: Kamba Tomomi 熊本大学, 大学院生命科学研究部(医), 教授 (20402836)
• Co-Investigator(Kenkyū-buntansha): 元島 崇信 熊本大学, 大学院生命科学研究部(医), 助教 (60726355) ; 山崎 俊成 京都大学, 医学研究科, 講師 (00607749) ; 小林 恭 京都大学, 医学研究科, 助教 (00642406) ; 寺田 直樹 京都大学, 医学研究科, 助教 (60636637) ; 小川 修 京都大学, 医学研究科, 教授 (90260611) ; 中村 英二郎 京都大学, 医学研究科, 特定准教授 (90293878)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: バイオマーカー / CTC / cfDNA

Outline of Final Research Achievements

The present study suggested that cfDNA and CTC were both potential biomarkers for predicting the efficacy of a therapeutic drug in or for monitoring the disease status of a patient with prostate cancer. The present study also demonstrated that mutations of VHL gene could be detectable using cfDNA from patients with VHL-defective renal cell carcinoma, which suggests the possibility of exploring useful biomarkers for renal cell carcinoma using cfDNA. Futhermore, our study suggested that precision medicine approach could be introduced according to the types of chimeric protein in patients with translocation renal cell carcinoma.

Free Research Field

泌尿器腫瘍学